



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

01 May 2021

COVID-19 vaccination status as of 0:00 today (cumulative since 26 February 2021)

	Total	City							
		Seoul	Busan	Daegu	Incheon	Gwangju	Daejeon	Ulsan	Sejong
New (1st dose)	259,018	37,847	20,355	11,692	14,515	6,763	7,371	3,809	1,037
New (1st dose)	29,655	4,278	1,779	1,604	1,601	1,181	517	1,144	346
Total (1st)	3,326,003	511,162	213,380	141,467	166,091	104,825	93,329	56,866	15,775
Total (2nd)	228,399	35,900	12,109	8,708	17,335	7,942	6,649	9,968	2,354
	Total	Province							
		Gyeonggi	Gangwon	Chung-buk	Chung-nam	Jeon-buk	Jeon-nam	Gyeong-buk	Gyeong-nam
New (1st dose)	61,313	11,443	9,109	13,324	11,190	15,580	16,971	13,631	3,068
New (1st dose)	5,026	1,388	1,897	1,384	1,442	1,856	1,795	1,716	701
Total (1st)	725,162	127,424	126,620	166,399	176,641	198,147	218,873	243,206	40,636
Total (2nd)	35,051	13,602	13,144	12,550	12,477	12,310	7,925	14,266	6,109

※ Figures subject to correction recording update

Adverse events following COVID-19 vaccination reported as of 0:00 today (cumulative since 26 February 2021)

		Vaccinated (cumulative)	Total	%	General ¹⁾	Anaphylaxis suspected ²⁾	Severe suspected ³⁾	Deaths
Total	New	3,554,402	697	0.46%	686	6	3	2
	Total		16,196		15,889	173	59	75
AstraZeneca	New	1,775,732	483	0.79%	478	4	1	0
	Total		13,968		13,752	139	34	43
Pfizer	New	1,778,670	214	0.13%	208	2	2	2
	Total		2,228		2,137	34	25	32

¹⁾ Mild cases such as headache, fever, nausea, vomiting, etc.

²⁾ Anaphylactoid reaction and anaphylactic shock suspected cases reported by healthcare institutions; Anaphylactoid reaction refers to occurrence of symptoms such as shortness of breath, rashes, etc. within 2 hours of vaccination and differs from anaphylaxis

³⁾ Includes convulsion and other nervous system response and ICU admitted cases

※ Based on the patient's condition at the time of initial report (general, anaphylaxis suspected, severe suspected, death)

※ Cases reported as suspected cases of AEFI; causal association not yet determined; investigation for assessment of causal association to take place for deaths or anaphylaxis cases



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

01 May 2021

Confirmed cases by gender and age group

		New cases (%)	Total cases (%)	Incidence rate* (per 100,000)
Total		627 (100)	122,634 (100)	236.53
Sex	Male	314 (50.08)	61,060 (49.79)	236.09
	Female	313 (49.92)	61,574 (50.21)	236.96
Age	80 or above	22 (3.51)	5,347 (4.36)	281.54
	70-79	39 (6.22)	8,861 (7.23)	245.65
	60-69	90 (14.35)	18,873 (15.39)	297.48
	50-59	120 (19.14)	22,689 (18.50)	261.79
	40-49	110 (17.54)	18,178 (14.82)	216.68
	30-39	93 (14.83)	16,524 (13.47)	234.55
	20-29	75 (11.96)	18,271 (14.90)	268.44
	10-19	48 (7.66)	8,578 (6.99)	173.63
	0-9	30 (4.78)	5,313 (4.33)	128.07

* Total (cumulative) number of cases reported since January 2020 by sex and age / Population by sex and age (based on resident registration data of the Ministry of the Interior as of January 2020)

※ Figures subject to correction based on findings from epidemiological investigations

Deaths and severe/critical patients by gender and age group

		New deaths (%)	Total deaths (%)	Case fatality rate (%)	Severe/critical (%)
Total		3 (100)	1,831 (100)	1.49	174 (100)
Sex	Male	2 (66.67)	910 (49.70)	1.49	113 (64.94)
	Female	1 (33.33)	921 (50.30)	1.50	61 (35.06)
Age	80 or above	1 (33.33)	1,006 (54.94)	18.81	45 (25.86)
	70-79	0 (0.00)	523 (28.56)	5.90	66 (37.93)
	60-69	2 (66.67)	216 (11.80)	1.14	38 (21.84)
	50-59	0 (0.00)	62 (3.39)	0.27	16 (9.20)
	40-49	0 (0.00)	14 (0.76)	0.08	6 (3.45)
	30-39	0 (0.00)	7 (0.38)	0.04	2 (1.15)
	20-29	0 (0.00)	3 (0.16)	0.02	1 (0.57)
	10-19	0 (0.00)	0 (0.00)	0.00	0 (0.00)
	0-9	0 (0.00)	0 (0.00)	0.00	0 (0.00)

* Case fatality rate (CFR) (%) = Number of deaths / Number of confirmed cases x 100

※ Figures subject to correction based on findings from epidemiological investigations

Age distribution of severe/critical patients

	4.18.	4.19.	4.20.	4.21.	4.22.	4.23.	4.24.	4.25.	4.26.	4.27.	4.28.	4.29.	4.30.	5.1.
Total	102	99	109	116	125	127	136	136	132	156	160	157	164	174

* Severe/Critical: COVID-19 patients in isolation being treated with high flow oxygen therapy, mechanical ventilator, ECMO (Extracorporeal Membrane Oxygenation), CRRT (Continuous Renal Replacement Therapy)